गुरुवार, 27 मई 2021

Acknowledgement of improvement in SMSRE 2021-22

 By e-mail

FORSE/SAIL-C/0721

May 27, 2021      

To

Ms Soma Mondal,

Chairman,

Steel Authority of India Ltd,

Ispat Bhavan, Lodhi Road, 

New Delhi – 110 003.

Sub: Acknowledgement of improvement in SAIL Mediclaim Scheme 2021-22.

Ref: Our FORSE/SAIL-C/0621 dated May 25, 2021

Madam,

This is to gratefully acknowledge the improvements indicated in SAIL Mediclaim Scheme for 2021-22 through the Tender documents floated by SAIL recently. In addition to some favourable changes in the cuppings on procedures/ packages, a look at the Tender document revealed the following positive changes. Madam, we are thankful to you for your kind initiative and approval to these improvements in the Scheme desired/ demanded by FORSE, some of them for over 7 years now. 

1)  IPD / Cashless treatment increased to Rs. 8.00 lakhs: Our long-term demand of IPD/ Cashless treatment has been increased from earlier Rs 4 lakhs to Rs. 8 lakhs with floater facilities.

2)  Treatment for Age Related Macular degeneration with Injection Avastin/Lucentis/Macugen: Rs.1,00,000 

3)   Robotic Surgery allowed.

4)  Premium for 80+: Only Rs 100 will be the registration fee for those who are 80 and above.

5)   Introduction of Tele-medicine and e-pharmacy

6)   Premium in respect of gap cases to be same as others

Madam, we request you to kindly take further cognizance and give serious sympathetic consideration to our Suggestions for improvement in Healthcare policy for SAIL Retirees (2021-22) and introduce necessary changes in OPD coverage for uniform application throughout the country so that the heart burning of discrimination in OPD coverage caused by locational disadvantage does not exist anymore. We also request for a SAIL-FORSE meeting with you, as per your convenience, so that communication gap is bridged.

With regards,

Yours faithfully,

For and on behalf of Federation of Retired SAIL Employees

(V. N. Sharma)

 Chairman               

(Ram Agar Singh(

 Gen Secretary

कोई टिप्पणी नहीं: